{{Drugbox
| verifiedrevid = 450846426
| IUPAC_name = 4,5α-Epoxy-3-hydroxy-14β-pentylamino-17-methyl-7,8-didehydromorphinan-6-one
| image = Pentamorphone2DCSD.svg
| width = 220

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = Schedule I
| legal_status =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number = 68616-83-1
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 5464186
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = MM4487B4MW
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D05416
| ChemSpiderID      = 4576571


<!--Chemical data-->
| C=22 | H=28 | N=2 | O=3 
| molecular_weight = 368.469 g/mol
| smiles = CCCCCN[C@@]12C=CC(=O)[C@H]3[C@@]14CCN([C@@H]2CC5=C4C(=C(C=C5)O)O3)C
| StdInChI          = 1S/C22H28N2O3/c1-3-4-5-11-23-22-9-8-16(26)20-21(22)10-12-24(2)17(22)13-14-6-7-15(25)19(27-20)18(14)21/h6-9,17,20,23,25H,3-5,10-13H2,1-2H3/t17-,20+,21+,22-/m1/s1
| StdInChIKey       = NRPCWSUJMWEFOK-KDXIVRHGSA-N
| synonyms =  
}}

'''Pentamorphone''' ('''14β-pentylaminomorphinone''', '''RX-77989''') is a semi-synthetic [[opiate]] derivative related to compounds such as [[morphine]], [[hydromorphone]] and [[oxymorphone]]. Developed in 1984, it is a potent opioid [[analgesic]] several times stronger than [[fentanyl]], and with a similarly fast onset of effects and short duration of action.<ref>Glass PS, Camporesi EM, Shafron D, Quill T, Reves JG. Evaluation of pentamorphone in humans: a new potent opiate. ''Anesthesia and Analgesia''. 1989 Mar;68(3):302-7. {{PMID|2465708}}</ref><ref>Rudo FG, Wynn RL, Ossipov M, Ford RD, Kutcher BA, Carter A, Spaulding TC. Antinociceptive activity of pentamorphone, a 14-beta-aminomorphinone derivative, compared to fentanyl and morphine. ''Anesthesia and Analgesia''. 1989 Oct;69(4):450-6. {{PMID|2476953}}</ref> It was found to produce relatively little [[respiratory depression]] compared to other potent opioid agonists,<ref>Afifi MS, Glass PS, Cohen NA, Shook JE, Camporesi EM. Depression of ventilatory responses to hypoxia and hypercapnia after pentamorphone. ''Anesthesia and Analgesia''. 1990 Oct;71(4):377-83. {{PMID|1698039}}</ref> but its analgesic effects were somewhat disappointing in human trials,<ref>Wong HY, Parker RK, Fragen R, White PF. Pentamorphone for management of postoperative pain. ''Anesthesia and Analgesia''. 1991 May;72(5):656-60. {{PMID|1708214}}</ref> and while pentamorphone had some slight advantages over fentanyl<ref>Kelly WB, Howie MB, Romanelli VA, Duarte JA, Rezaei H, McSweeney TD. A comparison of pentamorphone and fentanyl in balanced anaesthesia during general surgery. ''Canadian Journal of Anesthesia''. 1994 Aug;41(8):703-9. {{PMID|7522977}}</ref> these were not sufficient to warrant its introduction into clinical use.

== References ==
{{Reflist|2}}


{{Opioidergics}}

[[Category:Morphinans]]
[[Category:Phenols]]
[[Category:Ketones]]
[[Category:Mu-opioid agonists]]
[[Category:Semisynthetic opioids]]


{{analgesic-stub}}